Literature DB >> 21793106

FAS mRNA editing in Human Systemic Lupus Erythematosus.

Jianming Wu1, Fenglong Xie, Kun Qian, Andrew W Gibson, Jeffrey C Edberg, Robert P Kimberly.   

Abstract

FAS/FASL system plays a central role in maintaining peripheral immune tolerance. Human Systematic Lupus Erythematosus (SLE) is a prototypic systemic autoimmune disease characterized by expansion of autoreactive lymphocytes. It remains unclear whether a defective FAS/FASL system is involved in the pathogenesis of SLE. In this study, we have discovered a novel nucleotide insertion in FAS mRNA. We demonstrate that this novel FAS mutation occurs at mRNA levels, likely through a site-specific mRNA editing process. The mRNA editing mutation is unique for human FAS because the similar mRNA editing event is absent in other human TNF receptor (TNFR) family genes with death domains (DR5, DR6, and TNFR1) and in murine FAS. The adenine insertion mutation in the coding region message causes the alteration of human FAS mRNA reading frame. Functionally, cells expressing the edited FAS (edFAS) were refractory to FAS-mediated apoptosis. Surprisingly, cells from SLE patients produced significantly more edFAS products compared to cells from normal healthy controls. Additionally, we demonstrated that persistent engagement of T-cell receptor increases human FAS mRNA editing in human T cells. Our data suggest that the site-specific FAS mRNA editing mutation may play a critical role in human immune responses and in the pathogenesis of human chronic inflammatory diseases.
© 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21793106      PMCID: PMC3196739          DOI: 10.1002/humu.21565

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  38 in total

1.  Human autoreactive and foreign antigen-specific T cells resist apoptosis induced by soluble recombinant CD95 ligand.

Authors:  F Zipp; R Martin; R Lichtenfels; W Roth; J Dichgans; P H Krammer; M Weller
Journal:  J Immunol       Date:  1997-09-01       Impact factor: 5.422

2.  A FAScinating receptor in self-tolerance.

Authors:  Madhu Ramaswamy; Richard M Siegel
Journal:  Immunity       Date:  2007-05       Impact factor: 31.745

3.  Transgenic expression of Fas in T cells blocks lymphoproliferation but not autoimmune disease in MRL-lpr mice.

Authors:  H Fukuyama; M Adachi; S Suematsu; K Miwa; T Suda; N Yoshida; S Nagata
Journal:  J Immunol       Date:  1998-04-15       Impact factor: 5.422

4.  Induction of specific T cell tolerance by Fas ligand-expressing antigen-presenting cells.

Authors:  H G Zhang; X Su; D Liu; W Liu; P Yang; Z Wang; C K Edwards; H Bluethmann; J D Mountz; T Zhou
Journal:  J Immunol       Date:  1999-02-01       Impact factor: 5.422

5.  The resistance of activated T-cells from SLE patients to apoptosis induced by human thymic stromal cells.

Authors:  V M Budagyan; E G Bulanova; N I Sharova; M F Nikonova; M L Stanislav; A A Yarylin
Journal:  Immunol Lett       Date:  1998-01       Impact factor: 3.685

6.  Frameshift mutants of beta amyloid precursor protein and ubiquitin-B in Alzheimer's and Down patients.

Authors:  F W van Leeuwen; D P de Kleijn; H H van den Hurk; A Neubauer; M A Sonnemans; J A Sluijs; S Köycü; R D Ramdjielal; A Salehi; G J Martens; F G Grosveld; J Peter; H Burbach; E M Hol
Journal:  Science       Date:  1998-01-09       Impact factor: 47.728

7.  The spectrum of apoptotic defects and clinical manifestations, including systemic lupus erythematosus, in humans with CD95 (Fas/APO-1) mutations.

Authors:  A K Vaishnaw; E Toubi; S Ohsako; J Drappa; S Buys; J Estrada; A Sitarz; L Zemel; J L Chu; K B Elkon
Journal:  Arthritis Rheum       Date:  1999-09

8.  Lymphoproliferative syndrome with autoimmunity: A possible genetic basis for dominant expression of the clinical manifestations.

Authors:  F Rieux-Laucat; S Blachère; S Danielan; J P De Villartay; M Oleastro; E Solary; B Bader-Meunier; P Arkwright; C Pondaré; F Bernaudin; H Chapel; S Nielsen; M Berrah; A Fischer; F Le Deist
Journal:  Blood       Date:  1999-10-15       Impact factor: 22.113

9.  Fas (CD95)-transduced signal preferentially stimulates lupus peripheral T lymphocytes.

Authors:  K Sakata; A Sakata; N Vela-Roch; R Espinosa; A Escalante; L Kong; T Nakabayashi; J Cheng; N Talal; H Dang
Journal:  Eur J Immunol       Date:  1998-09       Impact factor: 5.532

10.  Elimination of antigen-presenting cells and autoreactive T cells by Fas contributes to prevention of autoimmunity.

Authors:  Peter B Stranges; Jessica Watson; Cristie J Cooper; Caroline-Morgane Choisy-Rossi; Austin C Stonebraker; Ryan A Beighton; Heather Hartig; John P Sundberg; Stein Servick; Gunnar Kaufmann; Pamela J Fink; Alexander V Chervonsky
Journal:  Immunity       Date:  2007-05       Impact factor: 31.745

View more
  3 in total

1.  Requirement of myeloid cell-specific Fas expression for prevention of systemic autoimmunity in mice.

Authors:  Carla M Cuda; Hemant Agrawal; Alexander V Misharin; G Kenneth Haines; Jack Hutcheson; Evan Weber; Joseph A Schoenfeldt; Chandra Mohan; Richard M Pope; Harris Perlman
Journal:  Arthritis Rheum       Date:  2012-03

Review 2.  CD95-mediated cell signaling in cancer: mutations and post-translational modulations.

Authors:  Sébastien Tauzin; Laure Debure; Jean-François Moreau; Patrick Legembre
Journal:  Cell Mol Life Sci       Date:  2011-11-01       Impact factor: 9.261

Review 3.  Fas Versatile Signaling and Beyond: Pivotal Role of Tyrosine Phosphorylation in Context-Dependent Signaling and Diseases.

Authors:  Krittalak Chakrabandhu; Anne-Odile Hueber
Journal:  Front Immunol       Date:  2016-10-17       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.